Titan Pharma (TTNP) Reports Q2 Loss of $0.11, Revenues Beat

Titan Pharma (NASDAQ: TTNP) reported Q2 EPS of ($0.11), versus ($0.20) reported last year. Revenue for the quarter came in at $1.6 million versus the consensus estimate of $100 thousand.

"In order to maximize the significant market opportunity represented by our lead product, Probuphine®, we were focused during the third quarter on successfully completing our transition to a commercial-stage company," said Titan\'s President and CEO, Sunil Bhonsle. "To that end, we strengthened our balance sheet via a public offering and completed the transfer of supply chain and logistics functions. More recently, Titan appointed Dane Hallberg to the newly created position of Executive Vice President and Chief Commercial Officer. Under Dane's leadership, we have rapidly built our commercial infrastructure, including a small, experienced and highly-accomplished sales, marketing and medical liaison team that has hit the ground running."

For earnings history and earnings-related data on Titan Pharma (TTNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c